On December 8, 2017 TG Therapeutics, Inc. (NASDAQ:TGTX), reported the schedule of data presentations for the Company’s lead compounds, TGR-1202, (umbralisib), the Company’s once-daily PI3K delta inhibitor, and TG-1101 (ublituximab), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, at the upcoming 59th American Society of Hematology (ASH) (Free ASH Whitepaper) annual meeting, being held December 9-12, 2017, at the Georgia World Congress Center in Atlanta, Georgia (Press release, TG Therapeutics, DEC 8, 2017, View Source [SID1234522474]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster presentations at the ASH (Free ASH Whitepaper) 2017 meeting include the following:
Sunday December 10, 2017:
Title: Phase I/II Study of Pembrolizumab in Combination with Ublituximab (TG-1101) and Umbralisib (TGR-1202) in Patients with Relapsed/Refractory CLL
• Abstract Number: 3010
• Session: 642. CLL: Therapy, excluding Transplantation: Poster II
• Date and Time: Sunday, December 10, 2017; 6:00 PM – 8:00 PM ET
• Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2
• Presenter: Anthony R. Mato, MD, University of Pennsylvania, Philadelphia, PA
Title: Umbralisib/TGR-1202 as a Novel Dual PI3K/CK1 Inhibitor Has a Unique Therapeutic Role in Silencing Oncogenes in Aggressive Lymphomas
• Abstract Number: 2809
• Session: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster II
• Date and Time: Sunday, December 10, 2017; 6:00 PM – 8:00 PM ET
• Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2
• Presenter: Ipsita Pal, PhD, Columbia University Medical Center, New York, NY
Title: Differential Regulation of T Cells By PI3K Delta Inhibitors in a CLL Murine Model
• Abstract Number: 3009
• Session: 642. CLL: Therapy, excluding Transplantation: Poster II
• Date and Time: Sunday, December 10, 2017; 6:00 PM – 8:00 PM ET
• Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2
• Presenter: Kamira K. Maharaj, BS, Moffit Cancer Center, Tampa, FL
Monday, December 11, 2017:
Title: An Integrated Safety Analysis of the Next Generation PI3Kδ Inhibitor Umbralisib (TGR-1202) in Patients with Relapsed/Refractory Lymphoid Malignancies
• Abstract Number: 4037
• Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III
• Date and Time: Monday, December 11, 2017; 6:00 PM – 8:00 PM ET
• Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2
• Presenter: Matthew S. Davids, MD, Dana Farber Cancer Institute, Boston, MA
Title: KI Intolerance Study: A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) in Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K-δ Inhibitor Therapy
• Abstract Number: 4314
• Session: 642. CLL: Therapy, excluding Transplantation: Poster III
• Date and Time: Monday, December 11, 2017; 6:00 PM – 8:00 PM ET
• Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2
• Presenter: Anthony R. Mato, MD, University of Pennsylvania, Philadelphia, PA
Title: PI3K-Delta Inhibitors Induce Primary Monocyte Cytotoxicity but Do Not Alter Monocyte Differentiation
• Abstract Number: 4284
• Session: 641. CLL: Biology and Pathophysiology, excluding Therapy: Poster III
• Date and Time: Monday, December 11, 2017; 6:00 PM – 8:00 PM ET
• Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2
• Presenter: Daphne Friedman, MD, Durham VA/Duke University Medical Center, Durham, NC
The above referenced abstracts can be viewed online through the ASH (Free ASH Whitepaper) meeting website at www.hematology.org. Following each presentation, the data presented will be available on the Publications page of the Company’s website at www.tgtherapeutics.com.
TG THERAPEUTICS INVESTOR & ANALYST EVENT
TG Therapeutics will also host a reception on Sunday, December 10, 2017 beginning at 8:00pm ET with featured presentations beginning promptly at 8:15pm ET. The event will take place at the Ritz Carlton Atlanta (Downtown) in the Salon I/II Room on the lower level. This event will be webcast live and will be available on the Events page, located within the Investors & Media section of the Company’s website at www.tgtherapeutics.com, as well as archived for future review. This event will also be broadcast via conference call. To access the conference line, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), and reference Conference Title: TG Therapeutics December 2017 Investor & Analyst Event.